(+) Targacept: Jefferies Global Healthcare Conference (Targacept) - Nov 22, 2013 - "TC-5619: Completed Phase 2 Trial in Schizophrenia Patients"; "Statistical significance in primary endpoint (executive function test) and secondary endpoint for negative symptoms; other cognitive endpoints yielded mixed results"; "Results driven by tobacco users"; "Generally well tolerated at all dose levels"
P2 data • Schizophrenia
|